These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8204512)

  • 41. Myelosuppression and "conventional" chemotherapy: what price, what benefit?
    Canellos GP; Demetri GD
    J Clin Oncol; 1993 Jan; 11(1):1-2. PubMed ID: 8418220
    [No Abstract]   [Full Text] [Related]  

  • 42. [Adult non-hodgkin lymphoma: Has high-dose chemotherapy improved the prognosis?].
    Hiddemann W
    Dtsch Med Wochenschr; 2011 Nov; 136(45):2293. PubMed ID: 22052589
    [No Abstract]   [Full Text] [Related]  

  • 43. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY.
    Avalos BR; Klein JL; Kapoor N; Tutschka PJ; Klein JP; Copelan EA
    Bone Marrow Transplant; 1993 Aug; 12(2):133-8. PubMed ID: 8401359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating hemopoietic progenitors mobilized by cancer chemotherapy and by rhGM-CSF in the treatment of high-grade non-Hodgkin's lymphoma.
    Bregni M; Siena S; Magni M; Bonadonna G; Gianni AM
    Leukemia; 1991; 5 Suppl 1():123-7. PubMed ID: 1716335
    [No Abstract]   [Full Text] [Related]  

  • 45. Chemotherapy-induced myelosuppression.
    Maxwell MB; Maher KE
    Semin Oncol Nurs; 1992 May; 8(2):113-23. PubMed ID: 1621002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease.
    Clarke K; Grigg A
    Leuk Lymphoma; 1995 Nov; 19(5-6):521-2. PubMed ID: 8590858
    [No Abstract]   [Full Text] [Related]  

  • 47. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
    Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
    Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
    LaCasce AS; Freedman AS
    Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth factors in the management of adult acute leukemia.
    Bernstein SH
    Hematol Oncol Clin North Am; 1993 Feb; 7(1):255-74. PubMed ID: 8449861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical trials referral resource. Non-Hodgkin's lymphoma.
    Cheson BD
    Oncology (Williston Park); 1989 Oct; 3(10):37-40, 45-50. PubMed ID: 2640585
    [No Abstract]   [Full Text] [Related]  

  • 52. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma.
    Rubino C; Laplanche A; Patte C; Michon J
    J Natl Cancer Inst; 1998 May; 90(10):750-5. PubMed ID: 9605644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
    Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
    Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of relapses in aggressive non Hodgkin's lymphoma.
    Bosly A
    Bull Cancer; 2004; 91(7-8):E261-73. PubMed ID: 15381464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Systemic therapy of low malignancy non-Hodgkin lymphomas].
    Wörmann B; Buske C; Hiddemann W
    Praxis (Bern 1994); 1998 Jun; 87(23):806-11. PubMed ID: 9654987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
    Blaise D; Faucher C; Vey N; Caraux J; Maraninchi D; Chabannon C
    Lancet; 2000 Oct; 356(9238):1325-6. PubMed ID: 11073025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of aggressive non-Hodgkin's lymphoma in aged patients with a combination of methyl-GAG, etoposide and prednimustine].
    Solal-Celigny P; Tertian G; Herrera A; Brousse N; Peuchmaur M
    Bull Cancer; 1990; 77(5):449-52. PubMed ID: 2400814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
    Laporte JP; Yeshurun M; Fouillard L; Labopin M; Cailliot C; Lesage S; Isnard F; Najman A; Gorin NC
    Leukemia; 2004 Oct; 18(10):1717-21. PubMed ID: 15295607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.